Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $107.4 million.

  • Tango Therapeutics' Shares Outstanding (Weighted Average) rose 3.84% to $111.3 million in Q3 2025 from the same period last year, while for Jun 2025 it was $108.4 million, marking a year-over-year increase of 1.45%. This contributed to the annual value of $107.4 million for FY2024, which is 5.32% up from last year.
  • Per Tango Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $107.4 million for FY2024, which was up 5.32% from $102.0 million recorded in FY2023.
  • Over the past 5 years, Tango Therapeutics' Shares Outstanding (Weighted Average) peaked at $107.4 million during FY2024, and registered a low of $21.4 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $99.2 million, with a median of $102.0 million in 2023.
  • Data for Tango Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY soared of 309.53% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Tango Therapeutics' Shares Outstanding (Weighted Average) stood at $21.4 million in 2020, then surged by 309.53% to $87.5 million in 2021, then increased by 0.72% to $88.2 million in 2022, then grew by 15.66% to $102.0 million in 2023, then rose by 5.32% to $107.4 million in 2024.